ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.52
-0.17%
US Tech 100
17,582.00
-0.17%
S&P 500
5,187.67
0.00%
US Dollar vs CAD
1.37235
-0.03%
Bitcoin
61,611.52
0.69%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) News

ATNM

Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:ATNM
DateTimeSourceHeadlineSymbolCompany
05/07/20247:00AMPR Newswire (US)Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas SouthwesternAMEX:ATNMActinium Pharmaceuticals Inc
04/18/20247:00AMPR Newswire (US)Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
04/01/20247:00AMPR Newswire (US)Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnualAMEX:ATNMActinium Pharmaceuticals Inc
03/26/20246:18AMPR Newswire (US)Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
03/11/20246:30AMPR Newswire (US)Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandAMEX:ATNMActinium Pharmaceuticals Inc
02/26/20246:30AMPR Newswire (US)Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTAMEX:ATNMActinium Pharmaceuticals Inc
02/23/20246:30AMPR Newswire (US)Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBAMEX:ATNMActinium Pharmaceuticals Inc
02/09/20243:30PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
02/05/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:ATNMActinium Pharmaceuticals Inc
02/02/20244:03PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
01/02/20246:30AMPR Newswire (US)Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®AMEX:ATNMActinium Pharmaceuticals Inc
12/29/20234:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
12/29/20234:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
12/29/20234:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
12/29/20234:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
12/29/20234:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
12/11/20237:15AMPR Newswire (US)Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationAMEX:ATNMActinium Pharmaceuticals Inc
12/11/20236:45AMPR Newswire (US)Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAMEX:ATNMActinium Pharmaceuticals Inc
12/08/20237:00AMPR Newswire (US)Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionAMEX:ATNMActinium Pharmaceuticals Inc
12/01/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:ATNMActinium Pharmaceuticals Inc
11/09/20234:09PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ATNMActinium Pharmaceuticals Inc
11/09/20234:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ATNMActinium Pharmaceuticals Inc
11/06/20236:30AMPR Newswire (US)Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsAMEX:ATNMActinium Pharmaceuticals Inc
11/02/20233:15PMPR Newswire (US)Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023AMEX:ATNMActinium Pharmaceuticals Inc
11/02/20238:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ATNMActinium Pharmaceuticals Inc
11/02/20238:05AMPR Newswire (US)Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialAMEX:ATNMActinium Pharmaceuticals Inc
10/04/20236:30AMPR Newswire (US)Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
09/27/20238:05AMPR Newswire (US)Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
09/07/20237:40AMPR Newswire (US)Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHOAMEX:ATNMActinium Pharmaceuticals Inc
08/31/20236:00AMPR Newswire (US)Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:ATNM

Your Recent History

USOTC
BMXI
Brookmount Explorations (PK)
USOTC
RONN
Ronn Motor (PK)
NASDAQ
HOLO
MicroCloud Hologram
USOTC
GSTC
Globestar Therapeutics (PK)
USOTC
KGKG
Kona Gold Beverage (PK)
USOTC
FLES
Auto Parts 4Less (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
ILST
International Star (PK)
NASDAQ
PLUG
Plug Power
USOTC
IBGR
Nexus Energy Services (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
PSRU
Valiant Eagle (PK)
USOTC
TKMO
Tekumo (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
IPIX
Innovation Pharmaceuticals (CE)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved